Geneva, Sept. 25 -- International Clinical Trials Registry received information related to the study (ACTRN12626001157369) titled 'EphA2 Chimeric Antigen Receptor (CAR) T cell Therapy for Children with Bone Tumours: A Phase I Clinical Trial' on Sept. 17.
Study Type: Interventional
Study Design:
Purpose: Treatment
Allocation: Non-randomised trial
Assignment: Single group
Type of endpoint: Safety
Primary Sponsor: Sydney Children's Hospitals Network
Condition:
Osteosarcoma
Ewing sarcoma
Osteosarcoma
Ewing sarcoma
Cancer - Children's - Other
Cancer - Bone
Intervention:
The E2CAR trial is a single arm intervention trial. Eligible participants' autologous T-cells will be collected via leukapheresis then the T cells will be genetically ...